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Objectives In France, the epidemiology of multiple sclerosis and its
functional consequences are little known. This study aims to describe
prevalence and consequences of MS in the French Population.
Methods Two large population-based surveys ‘‘Disability health
household’’ and ‘‘Disability health institutions’’ interviewed
individuals living in France. Information about medical conditions,
impairments, disabilities, and participation restriction was col-
lected. Participants reporting multiple sclerosis as medical
condition were speciﬁcally analyzed. Through sampling and
weighted analysis of 33,896 structured interviews, 49,028,826
individuals living in France were represented.
Results The study showed a prevalence of self-reported MS of
211.8/100,000 (CI95% 157.5–266.1). The sex ratio was 2.91 (CI95%
1.85–4.57) women for one man. A north/south gradient did not
appear. Mean age was 52 years (SD 1.37). Participants who
declaredMS reported fatigue for 86.8% (IC95% 79.8–95.8), mobility
impairments for 75.9% (IC95% 65.8–86.1) and balance disorders for
65.6% (IC95% 54.6–76.7). Rates were respectively 44.9% (IC95% 44–
45.9), 11% (IC95% 10.6–11.5) and 6.4% (IC95% 6.1–6.7) for subjects
who did not report MS. Regarding difﬁculties in carrying out
activities of daily living, 24.8% of MS subjects were dependant for
washing, 17.3% for transfers, 12% for continence and 7.3% for
feeding. 68.9% of subjects had an EDSS score below or equal to 4
and 7.9% higher or equal to 7.5.
Discussion Our study showed a higher prevalence of multiple
sclerosis in France than previous French estimations did (between
60 and 142/100,000). Recent studies completed in other European
countries resulted in similar results. This strengthens the
hypothesis that prevalence of MS has increased. Improvements
in diagnosis of MS and the declarative method of the survey might
partly explain this higher prevalence ﬁgure. However, further
studies would be required to document and explain the increased
prevalence of this pathology, which has heavy functional
consequences.
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Objective Improvement of spatiotemporal gait parameters with
dalfampridine.
Method Retrospective study of data collected prospectively in
patients with multiple sclerosis treated by dalfampridine for gait
disorders. Spatiotemporal gait parameters [1] were measured
using a locometer at spontaneous and supported velocity after the
establishment of dalfambridine and after 14 days of treatment. In
addition, a clinical examination and Time 25 Foot Walk Test
(T25FW) were executed.
Results Two hundred patients with dalfampridine were
evaluated between April 2013 and September 2014. Eighty-six
patients had exploitable gait analysis (age: 53.3  9.5; median
EDSS: 5.5 [max: 6.5; min: 4]). Forty-one (47.6%) were classiﬁed as
responders (R) to the dalfampridine after improving their T25FWT of
over 20% and 45 (52.3%) as non-responders (NR). The dalfampridine
improved the spontaneous and supported walking velocity in the 2
groups (P < 0.05). The cadence and stride length improved in the 2
groups independently of the velocity (P < 0.05). On D14, the NR
became asymmetrical (P < 0.001) in spontaneous velocity. There was
an inverse correlation between spontaneous walking velocity to D0
and the % of improvement T25FWT (r = –0.524; P < 0.0001).
Discussion Dalfampridine improves some spatiotemporal gait
parameters in R as in NR but NR become asymmetrical at
spontaneous velocity. The lack of improvement in voluntarymotor
function could explain this asymmetry. Spontaneous walking
speed measured with locometer could be a predictive factor of
response to dalfampridine.
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